

# AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

NCT05848713

---

Status	RECRUITING
Phase	Phase 3
Sponsor	University of Manitoba
Enrollment	4,000 participants

## Key Eligibility Criteria

---

### Inclusion (7)

- Patients e18 years of age
  - Admitted to hospital for a suspected or confirmed diagnosis of CAP defined by:
  - Radiographic evidence of new or worsening infiltrate
  - One or more of the following signs and/or symptoms of lower respiratory tract infection
  - i. New or increased cough or sputum production ii. Fever of  $\geq 37.8^{\circ}\text{C}$  or temperature  $< 36^{\circ}\text{C}$  iii. WBC  $\geq 11 \times 10^9/\text{L}$  or  $< 4 \times 10^9/\text{L}$
  - c. The primary diagnosis is believed to be CAP as per the attending physician
- ... and 2 more (see full listing online)

### Exclusion (19)

- Suspected or confirmed active COVID-19 infection
  - Hospital admission for  $\geq 72$  hours prior to randomization
  - Patients receiving non-invasive or invasive ventilation, vasopressors, or extracorporeal life support (ECLS) within an ICU at the time of enrollment
  - Requirement for chronic mechanical ventilation via tracheostomy prior to hospitalization
  - Patients for whom the intent is to not use pharmacologic thromboprophylaxis
- ... and 14 more (see full listing online)

## Locations (62 total)

---

University of Chicago, Chicago, Illinois, United States  
Ochsner Clinic, Jefferson, Louisiana, United States  
Maine Medical Centre, Portland, Maine, United States  
... and 59 more locations

---

<https://clinicaltrials.gov/study/NCT05848713>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).